1CHEN Y Z, WANG D K. Physiological characteristics of in- flammatory bowel disease of the colon and colon-specific drug delivery[J]. Chin PharmJ, 2006, 41(2): 86.
2Rutgeerts P, Vermeire S, Van Assche G. Biological thera- pies for inflammatory bowel diseases[J]. Gastroenterology, 2009, 136(5): 1844.
4Moroi R, Endo K, Kinouchi Y, et al. FC~R3A-158 poly- morphism influences the biological response to inflixirnab in Crohn's disease through affecting the ADCC activity[J]. Im- munogenetics, 2013, 65(4): 265.
5Biancheri P, Di Sabatino A, Rovedatti L, et al. Effect of tu- mor necrosis factor-a blockade on muco~l addressin cell-adhe- sion molecule-1 in Crohn's disease[J]. Inflamm Bowel Dis, 2013, 19(2): 259.
7Rigby W F. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior [J]. Nat Clin Pract Rheumatol, 2007, 3(4) : 227.
8Lfigering A, Schmidt M, Liigering N, et al. Infliximab in- duces apoptosis in monocytes from patients with chronic ac- tive Crohn's disease by using a easpase-dependent pathway [J]. Gastroenterology, 2001, 121(5): 1145.
9ten Hove T, van Montfrans C, Peppelenbosch M P, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn' s disease [J]. Gut, 2002, 50 (2) : 206.
10Bruewer M, Luegering A, Kucharzik T, et al. Proinflamma- tow cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms [ J ]. J hnmunol, 2003, 171 ( 11 ) : 6164.
3Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists - passive-aggressive behavior? Nat Clin Pract Rheumatol, 2007, 3 (4): 227- 233.
4Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase- dependent pathway. Gastroenterology, 2001, 121 (5): 1145-1157.
5ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 2002, 50 (2): 206-211.
6Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol, 2003, 171 (11): 6164-6172.
7Targan SR, Hanauer SB, van Deventer SJ, et al. A short- term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 1997, 337 (15): 1029-1035.
8Hanauer SB, Feagan BG, Lichtenstein GR, et al;ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT Ⅰ randomised trial. Lancet, 2002, 359 (9317): 1541-1549.
9Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn' s disease. N Engl J Med, 1999, 340 (18): 1398-1405.
10Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 2004, 350 (9): 876-885.
3Van Assche G, Dignass A, Panes J, et al. The second European evi- dence-based Consensus on the diagnosis and management of Crohn' s disease: Definitions and diagnosis. J Crohns Colitis, 2010,4(1):7- 27.
4Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol, 2001,96(3):635-643.
5Koksal AR, Alkim C, Altinkaya E, et al. Infliximab- and azathio- prine-related severe neutropenia and thrombocytopenia in a case with Crohn' s disease. Turk J Gastroenterol, 2011,22(5):537-539.
6Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn' s disease. Am J Gastroenterol, 2009,104(10):2524-2533.
7Daperno M, D'Haens G, Van Assche G, et al. Development and val- idation of a new, simplified endoscopic activity score for Crohn' s disease: the SES-CD. Gastrointest Endosc, 2004,60(4):505-512.
8Molander P, Sipponen T, Kemppainen H, et al. Achievement of deep remission during scheduled maintenance therapy with TNFalpha- blocking agents in IBD. J Crohns Colitis, 2013,7(9):730-735.
9Targan SR, Hanauer SB, van Deventer S J, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 1997,337(15): 1029-1035.
10Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inflix- imab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002,359(9317):1541-1549.
